scholarly journals Worldwide epidemiology of diabetes-related end-stage renal disease, 2000–2015

2020 ◽  
Author(s):  
Hui-Teng Cheng ◽  
Xiaoqi Xu ◽  
Paik Seong Lim ◽  
Kuan-Yu Hung
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Annual Incidence ◽  
Western Pacific ◽  
Diabetic Patients ◽  
Patients With Diabetes ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients ◽  
The Western Pacific

Objective <p>The annual risk among diabetic patients to reach end-stage renal disease (ESRD) is largely unknown worldwide. This study aimed to compare the incidence of diabetes-related ESRD by creating a global atlas during 2000–2015.</p> <p>Research Design and Methods</p> <p>The annual incidence of ESRD among diabetic patients was calculated as the quotient of the number of incident ESRD patients with diabetes divided by the total number of patients with diabetes after subtracting the number with existing ESRD. The estimated ESRD prevalence and annual incidence were validated using the data provided by Fresenius Medical Care, Germany, and previously reported data, respectively.</p> <p>Results</p> <p>Data were obtained from 142 countries, covering 97·3% of the world population. The global percentage of the prevalent ESRD patients with DM increased from 19·0% in 2000 to 29·7% in 2015 worldwide, while the percentage of incident ESRD patients due to DM increased from 22·1% to 31·3%. The global annual incidence of ESRD among DM patients increased from 375·8 to 1016·0/million with DM during 2000–2015. The highest average rates were observed in the Western Pacific Region. Comparatively, the rates of incident ESRD among European DM patients ranged from half (309·2 vs 544·6) to a third (419·4 vs 1245·2) of the rates of the Western Pacific population during 2000–2015.</p> <p>Conclusions </p> <p>Great and nonrandom geographic variation in the annual rates among diabetic patients to reach ESRD suggests that distinct healthcare, environmental, and/or genetic factors contribute to the progression of diabetic kidney disease. Measures to prevent and treat DM-related ESRD require better patient susceptibility stratification.</p>

scholarly journals Worldwide epidemiology of diabetes-related end-stage renal disease, 2000–2015

2020 ◽  
Author(s):  
Hui-Teng Cheng ◽  
Xiaoqi Xu ◽  
Paik Seong Lim ◽  
Kuan-Yu Hung
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Annual Incidence ◽  
Western Pacific ◽  
Diabetic Patients ◽  
Patients With Diabetes ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients ◽  
The Western Pacific

Objective <p>The annual risk among diabetic patients to reach end-stage renal disease (ESRD) is largely unknown worldwide. This study aimed to compare the incidence of diabetes-related ESRD by creating a global atlas during 2000–2015.</p> <p>Research Design and Methods</p> <p>The annual incidence of ESRD among diabetic patients was calculated as the quotient of the number of incident ESRD patients with diabetes divided by the total number of patients with diabetes after subtracting the number with existing ESRD. The estimated ESRD prevalence and annual incidence were validated using the data provided by Fresenius Medical Care, Germany, and previously reported data, respectively.</p> <p>Results</p> <p>Data were obtained from 142 countries, covering 97·3% of the world population. The global percentage of the prevalent ESRD patients with DM increased from 19·0% in 2000 to 29·7% in 2015 worldwide, while the percentage of incident ESRD patients due to DM increased from 22·1% to 31·3%. The global annual incidence of ESRD among DM patients increased from 375·8 to 1016·0/million with DM during 2000–2015. The highest average rates were observed in the Western Pacific Region. Comparatively, the rates of incident ESRD among European DM patients ranged from half (309·2 vs 544·6) to a third (419·4 vs 1245·2) of the rates of the Western Pacific population during 2000–2015.</p> <p>Conclusions </p> <p>Great and nonrandom geographic variation in the annual rates among diabetic patients to reach ESRD suggests that distinct healthcare, environmental, and/or genetic factors contribute to the progression of diabetic kidney disease. Measures to prevent and treat DM-related ESRD require better patient susceptibility stratification.</p>

scholarly journals Diabetic nephropathy as a cause of end-stage renal disease in Egypt: a six-year study

2004 ◽  
Vol 10 (4-5) ◽  
pp. 620-626 ◽  
Author(s):  
A. Afifi ◽  
M. El Setouhy ◽  
M. El Sharkawy ◽  
M. Ali ◽  
H. Ahmed ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Large Scale ◽  
Cross Sectional Study ◽  
Diabetic Patients ◽  
Cross Sectional ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

The prevalence of diabetic nephropathy as a cause of end-stage renal disease [ESRD] in Egypt has been examined in small cross-sectional studies, with conflicting results. The need for a large-scale study prompted us to perform this 6-year multiple cross-sectional study. A sample of ESRD patients enrolled in the Egyptian renal data system was evaluated during the period 1996-2001 for the prevalence of diabetic nephropathy. Prevalence gradually increased from 8.9% in 1996, to 14.5% in 2001. The mean age of patients with diabetic nephropathy was significantly higher than that of patients with ESRD from other causes. Mortality was also significantly higher in diabetic patients with ESRD

MO641IMPACT OF MAGNESIUM AND L-CARNITINE ADMINISTRATION ON 3-YEAR SURVIVAL IN DIABETIC PATIENTS WITH END-STAGE RENAL DISEASE

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Oleksandr Susla ◽  
Zoriana Litovkina ◽  
Olha Bushtynska
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Cardiovascular Complications ◽  
Diabetic Patients ◽  
Carnitine Supplementation ◽  
Basic Therapy ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Abstract Background and Aims According to population registries, the survival of diabetic patients with end-stage-renal disease (ESRD) remains low today. In this context, it is reasonable to develop new therapeutic strategies based on advances in science of the important role of magnesium (Mg) and L-carnitine deficiency (via inflammation and endothelial dysfunction) in mechanisms of cardiovascular remodeling, high morbidity and mortality rates. Thus, the purpose of the present study was to evaluate the effect of Mg and L-carnitine supplementation on 3-year survival and development of the cardiovascular complications in diabetic hemodialysis (HD) patients. Method 48 type 2 diabetic ESRD patients were included in this prospective cohort study (male/female, 29/19; age, 59.9±0.6 years; HD duration, 34.8±4.8 month; diabetes mellitus duration, 174.7±7.1 month). The study was performed in accordance with the provisions of the Declaration of Helsinki last revision. Depending on the treatment programme, patients were divided into two groups: the 1st (main) group (n=24) in addition to basic treatment (hypoglycemic, antihypertensive therapy, according to indications - correction of anemia, hyperparathyroidism, hyperphosphatemia) was treated by combination of magnesium aspartate (0.5 g/day orally) and L-carnitine (1 g/day parenterally after each HD session (three times weekly); the 2nd (comparison) group (n=24) was only on the basic therapy. Complex treatment lasted 12-months; administration of L-carnitine was performed continuously throughout the year, while magnesium aspartate – by three 2-months’ courses/year. The follow up period in both groups was 36 months. Quantitative data are expressed as means±SEM, qualitative ones – as %. Kaplan-Meier method and Log-rank test were used to estimate survival of HD patients, χ2-test – to compare the frequency values. Results The cumulative proportion of survivors at the end of follow-up was 60.4%; however, after 36 months, the survival rate of diabetic HD patients who received a combination of magnesium aspartate and L-carnitine as part of their modified treatment was significantly higher (75 vs. 45.8%; Log-rank=2.07, p=0.038) compared to patients who were on basic therapy (Figure). Survival time in main and comparison groups was 31.9±1.7 and 26.4±2.2 months respectively. It is noteworthy, that throughout the year (from 10 to 22 months), no completed events were recorded in subjects who underwent Mg and L-carnitine supplementation. Conclusion (1) The combined use of magnesium aspartate and L-carnitine in addition to the basic 12-month treatment provides an effective reduction of cardiovascular complications and promotes 3-year survival of diabetic HD patients. (2) The results obtained substantiate the advisability of using repeated courses of Mg and L-carnitine administration 1 years after the end of the primary modified treatment to improve the prognosis in these ESRD patients.

Abstract 370: Contrast-Induced Nephropathy and Long-Term Outcomes in Patients With Diabetes Undergoing Coronary and Peripheral Angiography and Intervention

2017 ◽  
Vol 37 (suppl_1) ◽  
Author(s):  
Dennis A Hopkinson ◽  
Samuel P Powell ◽  
Raveen Chawla ◽  
Wendy Bottinor ◽  
Jeremy S Turlington ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Diabetic Group ◽  
Diabetic Patients ◽  
Long Term Outcomes ◽  
Peripheral Angiography ◽  
Patients With Diabetes ◽  
Stage Renal Disease ◽  
End Stage

Background: Patients with diabetes may be at increased risk of contrast-induced nephropathy (CIN) when undergoing coronary and/or peripheral angiography or intervention but there is little data on long-term outcomes. We examined the relationship between diabetes, CIN and long-term outcomes in patients undergoing coronary and/or peripheral angiography and intervention. Methods and Results: We studied 4070 consecutive, predominantly (98%) male patients undergoing coronary and peripheral angiography and intervention and assessed the association between diabetes, CIN and long-term outcomes including renal dysfunction at 3 months, the need for dialysis and mortality. The mean age of the patients was 66.6 years. Approximately two fifths of the patients (n=1671, 41.05%) were diabetic. Patients with diabetes were the same age but had higher baseline creatinine compared to the patients without diabetes. CIN occurred in 70 (4.19%) diabetic patients and in 64 (2.67%) patients without diabetes at 72 hours after the procedure (odds ratio [OR] 1.59; 95% confidence interval [CI] 1.13 - 2.25; P=0.008). At 3 months, renal dysfunction was seen in 179 (10.71%) diabetic patients versus 174 (7.25%) of the non-diabetic group (OR 1.53, CI 1.23 - 1.91; P=0.0001). After a follow-up of 5 years, 31 (1.86 %) patients with diabetes had developed end-stage renal disease and were started on dialysis versus 13 (0.54 %) of the non-diabetic group (OR 3.47, CI 1.81 - 6.65; P<0.0001). 478 (28.61 %) patients of the diabetic group had died versus 479 (19.97 %) of the non-diabetic group (OR 1.61, CI 1.39 - 1.86; P<0.0001). On multivariate analysis, after adjustment for age, comorbidities, medical therapy and baseline creatinine, the presence of diabetes was significantly associated with CIN (OR 1.50, CI 1.06 - 2.43: p=0.02) and was significantly associated with the incidence of end stage renal disease requiring dialysis (OR 3.64, CI 2.07-10.04; P<0.0001) and with mortality at 5 years (OR 1.58, CI 1.42-2.03, P<0.0001). Conclusion: In this cohort of patients undergoing coronary and/or peripheral angiography and intervention diabetes was associated with CIN, with end-stage renal disease and the need for hemodialysis and was associated with an increased mortality.

Peritoneal Dialysis in Patients with Diabetes: Are the Benefits Greater than the Disadvantages?

2007 ◽  
Vol 27 (2_suppl) ◽  
pp. 190-195 ◽  
Author(s):  
Satoru Kuriyama
Keyword(s):  
Diabetic Nephropathy ◽  
Peritoneal Dialysis ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Diabetic Patients ◽  
Dialysis Modality ◽  
Patients With Diabetes ◽  
Stage Renal Disease ◽  
End Stage ◽  
Selection Of

Diabetic nephropathy has been increasing in prevalence in recent years, and it is now the dominant cause of end-stage renal disease (ESRD) worldwide. Because diabetes is frequently associated with multiple complications, nephrologists must be alert to the selection of dialysis modality so as to reduce the accompanying risks. The present review addresses whether the benefits of peritoneal dialysis are greater than its disadvantages in diabetic patients. The answer is quite positive: for most diabetic patients, peritoneal dialysis offers multiple benefits.

Peritoneal Dialysis as an Option for Unplanned Dialysis Initiation in Patients with End-Stage Renal Disease and Diabetes Mellitus

2018 ◽  
Vol 47 (1-3) ◽  
pp. 52-57 ◽  
Author(s):  
Haijiao Jin ◽  
Zhaohui Ni ◽  
Xiajing Che ◽  
Leyi Gu ◽  
Mingli Zhu ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Patient Survival ◽  
Short Term ◽  
Patients With Diabetes ◽  
Long Term Prognosis ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Aims: This study aimed to compare the short-term complications and long-term prognosis between urgent-start peritoneal dialysis (PD) and hemodialysis (HD), and explore the safety and feasibility of PD in end-stage renal disease (ESRD) patients with diabetes. Methods: This retrospective study enrolled ESRD patients with diabetes who required urgent-start dialysis at a single center from January 2011 to December 2014. Short-term (30-day) dialysis-related complications and patient survival trends were compared between patients receiving PD and HD. Results: Eighty patients were included in the study, including 50 (62.5%) who underwent PD. The incidence of dialysis-related complications and complications requiring reinsertion during the first 30 days was significantly lower in PD patients. Logistic regression identified urgent-start HD as an independent risk factor for dialysis-related complications compared with urgent-start PD. The patient survival rate was higher in the PD compared to that in the HD group. Conclusions: PD may be acceptable, safe, and feasible for urgent-start dialysis in ESRD patients with diabetes.

scholarly journals Platelet turnover and function in end-stage renal disease

2018 ◽  
Vol 75 (6) ◽  
pp. 604-610
Author(s):  
Predrag Filipov ◽  
Dusan Bozic ◽  
Romana Mijovic ◽  
Gorana Mitic
Keyword(s):  
Platelet Aggregation ◽  
Renal Disease ◽  
Chronic Inflammation ◽  
End Stage Renal Disease ◽  
Diabetic Patients ◽  
Reticulated Platelets ◽  
Stage Renal Disease ◽  
End Stage ◽  
And Function ◽  
Esrd Patients

Background/Aim. End-stage renal disease (ESRD) is characterized by significant impairment of platelet functions which may cause bleeding or thrombotic complications. The iam of this study was the aim of this study was the assessement of platelet turnover and function and their correlation with inflammatory and procoagulant markers in ESRD patients as well as platelet indicies comparison between ESRD diabetic and ESRD non-diabetic patients. Methods. The prospective, observational clinical study included 63 ESRD patients and 30 age and sex matched healthy volunteers. Following laboratory parameters of platelet turnover and function (platelet count, reticulated platelets, platelet indices, whole blood impedance platelet aggregation), inflammatory and procoagulant markers (number of neutrophils, neutrophil to lymphocyte ratio, C-reactive protein, plasma fibrinogen, D dimer, von Willebrand factor) were obtained. Results. Platelet turnover (% of reticulated platelets) was significantly higher (3.8 ? 2.3 vs. 2.3 ? 1.3; p < 0.01) and platelet aggregation tests induced by thrombin receptor activiting peptide (TRAP) (p < 0.01), adenosine diphospate (ADP) (p < 0.05), arachidonic acid (ASPI) (p < 0.05) and collagen (p < 0.05) were markedly increased in the ESRD patients compared to the control group. The comparison of chronic inflammation and procoagulant markers revealed higher values in all patients comparing to the group of healthy subjects (p < 0.01 regarding all parameters). There was no difference between the ESRD diabetic and ESRD non-diabetic patients. Conclusion. Results point out increased platelet turnover in ESRD as a consequence of platelet activation and consumption induced by clotting system hyperactivity and chronic inflammation. None of the examined parameters do not predict bleeding occurrence.

Adipokines and Gut Hormones in End-Stage Renal Disease

2007 ◽  
Vol 27 (2_suppl) ◽  
pp. 298-302
Author(s):  
Robert H. Mak ◽  
Wai Cheung
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Peptide Yy ◽  
Gut Hormones ◽  
Poor Quality ◽  
Mortality And Morbidity ◽  
Novel Therapeutic Strategies ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Cachexia is common in end-stage renal disease (ESRD) patients, and it is an important risk factor for poor quality of life and increased mortality and morbidity. Chronic inflammation is an important cause of cachexia in ESRD patients. In the present review, we examine recent evidence suggesting that adipokines or adipocytokines such as leptin, adiponectin, resistin, tumor necrosis factor α, interleukin-6, and interleukin-1β may play important roles in uremic cachexia. We also review the physiology and the potential roles of gut hormones, including ghrelin, peptide YY, and cholecystokinin in ESRD. Understanding the molecular pathophysiology of these novel hormones in ESRD may lead to novel therapeutic strategies.

scholarly journals Prevalence and Associated Factors of Frailty and Mortality in Patients with End-Stage Renal Disease Undergoing Hemodialysis: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 18 (7) ◽  
pp. 3471
Author(s):  
Hyeon-Ju Lee ◽  
Youn-Jung Son
Keyword(s):  
Systematic Review ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Associated Factors ◽  
Meta Analysis ◽  
Screening Tools ◽  
Cochrane Library ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Hemodialysis is the most common type of treatment for end-stage renal disease (ESRD). Frailty is associated with poor outcomes such as higher mortality. ESRD patients have a higher prevalence of frailty. This systematic review and meta-analysis aimed to identify the prevalence and associated factors of frailty and examine whether it is a predictor of mortality among ESRD patients undergoing hemodialysis. Five electronic databases including PubMed, Embase, CINAHL, Web of Science, and Cochrane Library were searched for relevant studies up to 30 November 2020. A total of 752 articles were found, and seven studies with 2604 participants in total were included in the final analysis. The pooled prevalence of frailty in patients with ESRD undergoing hemodialysis was 46% (95% Confidence interval (CI) 34.2−58.3%). Advanced age, female sex, and the presence of diabetes mellitus increased the risk of frailty in ESRD patients undergoing hemodialysis. Our main finding showed that patients with frailty had a greater risk of all-cause mortality compared with those without (hazard ratio (HR): 2.02, 95% CI: 1.65−2.48). To improve ESRD patient outcomes, healthcare professionals need to assess the frailty of older ESRD patients, particularly by considering gender and comorbidities. Comprehensive frailty screening tools for ESRD patients on hemodialysis need to be developed.

Sign in / Sign up

Export Citation Format

Share Document